Home Featured Page 127

Featured

Latest

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on Psychedelic Science, AI, and Idealist Monism

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

atai Life Sciences Announces Positive Initial Results for Phase 1 Trial...

FILAMENT HEALTH TO HOST VIRTUAL INVESTOR UPDATE

Reunion Neuroscience CEO to Participate on Panel at 2022 Horizons Perspectives...

COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in...

Clearmind Medicine Featured in “Psychedelics Tonight,” Streaming on ALTRD.TV

PsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical Trial

PT363 – Reggie Harris – Cannabis and Psilocybin: The Complications of...

Optimi Health Announces Closing of Strategic Non-Brokered Private Placement

Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for...

The Fifteenth Horizons is Right Around the Corner

1...126127128...292 Page 127 of 292

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on...

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on Psychedelic Science, AI, and Idealist Monism

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

atai Life Sciences Announces Positive Initial Results for Phase 1 Trial...

FILAMENT HEALTH TO HOST VIRTUAL INVESTOR UPDATE

Reunion Neuroscience CEO to Participate on Panel at 2022 Horizons Perspectives...

COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in...

Clearmind Medicine Featured in “Psychedelics Tonight,” Streaming on ALTRD.TV

PsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical Trial

PT363 – Reggie Harris – Cannabis and Psilocybin: The Complications of...

Optimi Health Announces Closing of Strategic Non-Brokered Private Placement

Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for...

The Fifteenth Horizons is Right Around the Corner

EDITOR PICKS

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on...

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY